Scholz, M <br/><br/>
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Mar 2011 
 - 681-688 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdq408  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Algorithms<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bleomycin--adverse effects<br/>Cyclophosphamide--adverse effects<br/>Dacarbazine--adverse effects<br/>Doxorubicin--adverse effects<br/>Etoposide--adverse effects<br/>Glyoxal--adverse effects<br/>Hodgkin Disease--drug therapy<br/>Humans<br/>Ifosfamide--adverse effects<br/>Kaplan-Meier Estimate<br/>Leukemia, Myeloid, Acute--chemically induced<br/>Lymphoma, Non-Hodgkin--chemically induced<br/>Myelodysplastic Syndromes--chemically induced<br/>Neoplasms, Second Primary--chemically induced<br/>Prednimustine--adverse effects<br/>Prednisone--adverse effects<br/>Procarbazine--adverse effects<br/>Proportional Hazards Models<br/>Randomized Controlled Trials as Topic<br/>Risk Assessment<br/>Treatment Outcome<br/>Vinblastine--adverse effects<br/>Vincristine--adverse effects